CELON PHARMA S.A.

Press Releases Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Market Closed - Warsaw S.E. Other stock markets 09:25:43 26/06/2024 pm IST			5-day change	1st Jan Change
15.68 ^PLN	+0.26%		-1.26%	+1.42%

17/06	Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl? 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra)	CI
22/05	Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

The results of CPL’36 – PDE10a inhibitor to be presented in the poster session at Neuroscience 2021.	02/21/02	PU
Celon Pharma S.A. at the Jefferies Healthcare Conference 2021.	26/21/26	PU
Celon Pharma S A : Doubled export sales, continuation of the strategy of investing in research and development	30/21/30	PU
Celon Pharma S A : 3 posters to be published at 34th ECNP Congress	14/21/14	PU
Celon Pharma S A : at EASD 2021	15/21/15	PU
Celon Pharma S A : Dynamic export and continuation of positive trends in the development of innovative products	26/21/26	PU
Celon Pharma S A : Capital Markets Day – 21.04.2021	30/21/30	PU
Celon Pharma S A : in the Stock Exchange Company of the Year ranking	19/21/19	PU
Celon Pharma S A : Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.	10/21/10	PU
Celon Pharma S A : at Top Picks by Trigon Investor Conference	18/21/18	PU
Celon Pharma S A : at J.P. Morgan Annual Healthcare Conference DIGITAL 11-14 January 2021 .	05/21/05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer